Search Medical Condition
Please enter condition
Please choose location from dropdown

Holiday, Florida Clinical Trials

A listing of Holiday, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (72) clinical trials

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.

Phase

2.87 miles

Learn More »

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ) Compared to Placebo and Adalimumab in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who have responded inadequately to MTX. The primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce the disease activity and ...

Phase

2.87 miles

Learn More »

Efficacy and Safety of Nipent Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Chronic Lymphocytic Leukemia (CLL) is the most common form of adult leukemia in the U.S. Recent experience with Nipent in conjunction with Rituxan has shown that this combination is well tolerated and is clinically promising. It is expected that the addition of Cytoxan in patients with previously untreated CLL and ...

Phase

2.87 miles

Learn More »

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.

Phase

2.87 miles

Learn More »

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Primary Objective: To demonstrate equivalence of Gan & Lee Insulin Glargine Injection and Lantus in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26

Phase

2.87 miles

Learn More »

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Primary Objective: To demonstrate equivalence of Gan & Lee Insulin Glargine Injection and Lantus in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26

Phase

2.87 miles

Learn More »

Evaluation of the Long Term Safety Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ) in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1 2 or 3.

The goal of this Phase III study is to evaluate the long-term safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who previously completed 24 weeks of double-blind treatment with OKZ in the core studies. OKZ is expected to reduce the disease activity and induce ...

Phase

2.87 miles

Learn More »

Effect of Efpeglenatide on Cardiovascular Outcomes

The estimated study duration per participant is up to approximately 36 months.

Phase

2.87 miles

Learn More »

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

The objective of this study is to evaluate efficacy and safety of risankizumab using a new formulation compared with placebo for treatment of moderate to severe plaque psoriasis.

Phase

2.87 miles

Learn More »

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

Phase

2.87 miles

Learn More »